Among the 22 renal transplant patients after PD-1 inhibitor treatment, 14 patients developed melanoma (13 cutaneous and one uveal), four developed cutaneous cSCC, two developed NSCLC, one developed a duodenal adenocarcinoma, and one developed urothelial carcinoma. The gene discussed is PDCD1; the disease is duodenal adenocarcinoma.